Lenalidomide for treatment of refractory aphthosis and neutrophilic pustulosis in familial pyrin-associated autoinflammation with neutrophilic dermatosis

Rheumatology (Oxford). 2023 Dec 1;62(12):e338-e340. doi: 10.1093/rheumatology/kead294.

Authors

Laura Poujade¹, Guillaume Sarrabay², Renaud Cezar³, Quentin Samaran¹, Pierre Corbeau³, Didier Bessis¹, Tu-Anh Tran⁴

Affiliations

¹ Department of Dermatology, Montpellier University Hospital, Montpellier, France.
² Department of Medical Genetics, Rare Diseases and Personalized Medicine, Montpellier University Hospital, Montpellier, France.
³ Laboratory of Immunology, Nîmes University Hospital, Nîmes, France.
⁴ Department of Paediatrics, Nîmes University Hospital, Nîmes, France.

PMID: 37314964
DOI: 10.1093/rheumatology/kead294

No abstract available

MeSH terms

Dermatitis*
Humans
Lenalidomide / therapeutic use
Neutrophils
Pyoderma Gangrenosum* / drug therapy
Pyrin
Stomatitis, Aphthous*

Substances

Pyrin
Lenalidomide